Life Sciences Innovator Poised for 35% Upside
Positioned at the heart of genomics and diagnostics, this mid-cap player combines recurring revenues with strategic buybacks, offering attractive upsi…
Please confirm you want to block this member.
You will no longer be able to:
Please allow a few minutes for this process to complete.